MERS coronavirusNIAIDUsing X-ray crystallography, researchers at Fudan University in Shanghai have identified two peptides from the Middle East respiratory syndrome coronavirus (MERS-CoV) that hint at the deadly pathogen’s ability to enter host cells via membrane fusion. They’ve also found that one of those peptides, called HR2P, can effectively inhibit MERS-CoV replication and fusion, such that “HR2P analogues have good potential to be further developed into effective viral fusion inhibitors for treating MERS-CoV infection,” the researchers reported in Nature Communications this week (January 28).

Both peptides are both part of the six-helix bundle fusion core structure of the MERS-CoV spike protein S2 subunit, through which viral and cell membranes can meet and fuse, releasing the viral genetic materials into the host cell cytoplasm.

In its paper, the Fudan team noted that the reported possibility of person-to-person transmission of the MERS-CoV points to its pandemic potential. Meanwhile, investigators from the...

Since September 2012, the World Health Organization (WHO) has counted 180 lab-confirmed cases of MERS-CoV infection worldwide, including 77 deaths. “MERS-CoV infections that may be acquired in health-care facilities illustrate the need to continue to strengthen infection prevention and control measures,” the WHO noted in its January 27 MERS-CoV update. “Health-care facilities that provide care for patients suspected or confirmed with MERS-CoV infection should take appropriate measures to decrease the risk of transmission of the virus to other patients, health care workers and visitors.”

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?